Centogene N.V. (CNTG)
| Previous close | 2.4700 |
| Open | 2.3900 |
| Bid | 2.6500 x 2200 |
| Ask | 2.7700 x 900 |
| Day's range | 2.3700 - 2.8295 |
| 52-week range | 1.8300 - 11.9500 |
| Volume | |
| Avg. volume | 9,127 |
| Market cap | 71.739M |
| Beta (5Y monthly) | -1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1970 |
| Earnings date | 01 July 2022 - 03 July 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.89 |
- GlobeNewswire
CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, today announced the voting results of the Company’s Annual General Meeting. Shareholders voted in favor of all proposals, which included the appointment of Miguel Coego Rios as Managing Director and Chief Financial Officer. The shareholders adopted the Dutch statutory annual account
- GlobeNewswire
CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer
Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFOCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, today announced the appointment of Miguel Coego Rios as Managing Director and Chief Financial Officer of the Company, effective June 22, 2022. “As we continue to make progress on pivoting the organization
- GlobeNewswire
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease
Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18Expanded collaboration to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies CENTOGENE’s genetic testing and Biodatabank identify causative mutations, including the UGT1A1 and PKLR genes, and supports precise diagnosis CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 13, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the comme
